Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01460433 · ClinicalTrials.gov registry record
Problems With Immune Recovery in the Gut Tissue
A clinical trial of Human Immunodeficiency Virus, sponsored by University of Minnesota.
- Completed
- Registry status
- 21
- Enrollment target
- 1
- Study location
NCT01460433: Completed study of Human Immunodeficiency Virus, sponsored by University of Minnesota.
NCT01460433 is a study of Human Immunodeficiency Virus that has completed, run by University of Minnesota. The registered enrollment target is 21 participants, below the 183-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01460433, a study of Human Immunodeficiency Virus, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to find out if the process of HIV replication in the lymph tissue and gut tissue of people taking HIV drugs causes long-term damage to the ability of the gut to protect you from other infections and health problems.
Conditions Studied
Interventions
- PROCEDURE Genital and rectal swabbing
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2008-09 |
| Est. Completion | 2013-01 |
What the finished NCT01460433 record still lists
NCT01460433 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 183-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Human Immunodeficiency Virus appearing as the primary indexed condition, and to 1 intervention - of which Genital and rectal swabbing is the first listed.
NCT01460433 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT01460433 about?
NCT01460433 is a clinical study titled "Problems With Immune Recovery in the Gut Tissue". The aim of this study is to find out if the process of HIV replication in the lymph tissue and gut tissue of people taking HIV drugs causes long-term damage to the ability of the gut to protect you from other infections and health problems.
What is the current status of trial NCT01460433?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2008-09. Estimated completion is 2013-01.
What conditions does trial NCT01460433 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus.
What interventions are being tested in trial NCT01460433?
The interventions under investigation include: Genital and rectal swabbing (PROCEDURE).
Who is sponsoring clinical trial NCT01460433?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01460433 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Immunodeficiency Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01460433's enrollment target sits among peer trials
21 30th of 39 higher than 9 of 39 other Human Immunodeficiency Virus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Human Immunodeficiency Virus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
Baricitinib for Reduction of HIV - CNS
RECRUITING · Phase 2
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
RECRUITING · Phase 2
-
Harm Reduction in HIV Primary Care for PLWH Who Use Drugs
RECRUITING
-
Tulane Abdominal Transplant Institute (TATI) of Solid Organ Transplantation of HIV-Positive Recipients From HIV-Positive Donors
RECRUITING
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia